Supplementary Material to

Cerebral μ-opioid and CB₁-receptor systems have distinct roles in human feeding behavior

Tatu Kantonen¹,², MD, Tomi Karjalainen¹, DSc (Tech), Laura Pekkarinen¹,³, MD, Janne Isojärvi¹, MSc, Kari Kalliokoski¹, PhD, Valtteri Kaasinen²,⁴, MD, PhD, Jussi Hirvonen¹,⁵, MD, PhD, Pirjo Nuutila¹,³, MD, PhD, and Lauri Nummenmaa¹,⁶, PhD

¹Turku PET Centre, University of Turku, Finland
²Clinical Neurosciences, University of Turku, Finland
³Department of Endocrinology, Turku University Hospital, Finland
⁴Neurocenter, Turku University Hospital, Finland
⁵Department of Radiology, University of Turku and Turku University Hospital, Finland
⁶Department of Psychology, University of Turku, Finland

Supplementary Material

i. PET scanners and smoking status (Supplementary Table 1)
ii. References for the original studies (Supplementary Table 2)
iii. Table of the p-values for descriptive correlations (Supplementary Table 3)
iv. Peak voxel coordinates for the full volume associations (Supplementary Table 4)
v. Scan acquisition and modeling in the PROSPECT (Supplementary Text 1)
vi. Complementary [¹¹C]carfentanil analyses (Supplementary Text 2)
vii. Descriptive correlations of the sample (Supplementary Figure 1)
viii. Visualization of regional associations in three representative regions of interest (Supplementary Figure 2)
ix. Regional correlations between MOR and CB₁R availabilities (Supplementary Figure 3)
x. External eating and μ-opioid receptor availability in males (Supplementary Figure 4)
PET scanners and smoking status

**Supplementary Table 1.** The information about PET scanners and smoking status of the sample.

| PET scanner (n)                                                                 | Males (n = 70) | Females (n = 22) |
|---------------------------------------------------------------------------------|----------------|------------------|
| High Resolution Research Tool (HRRT, Siemens Medical Solutions)                 | 8              | 9                |
| Discovery 690 PET/CT (GE Healthcare)                                            | 10             | 13               |
| GE Discovery VCT PET/CT (GE Healthcare)                                         | 52             | 0                |

| Smoking status (n)*               |                  |                  |
|-----------------------------------|------------------|------------------|
| Smoking                           | 0                | 7                |
| Nonsmoking                        | 57               | 15               |
| Unknown                           | 13               | 0                |

* The 13 individuals whose smoking status was unknown were classified as nonsmokers because in Finland, less than 20% of the adult population smoked cigarettes in 2000 ([http://urn.fi/URN:NBN:fi-fe2018102938947](http://urn.fi/URN:NBN:fi-fe2018102938947)). Results were similar in a parallel analysis where individuals with unknown smoking status were classified as smokers.
References for the original studies

**Supplementary Table 2.** The references for the original studies whose applicable healthy controls were included in the current study sample (n = 92 [11C]carfentanil scans).

- Majuri J *et al.* Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating. *Neuropsychopharmacology* 2017; **42**(5): 1169-1177.
  - 17 subjects (8 males and 9 females) scanned with High Resolution Research Tool (HRRT, Siemens Medical Solutions).

- Tuulari JJ *et al.* Feeding Releases Endogenous Opioids in Humans. *J Neurosci* 2017; **37**(34): 8284-8291.
  - 10 male subjects scanned with Discovery 690 PET/CT (GE Healthcare).

- Karlsson HK *et al.* Obesity is associated with decreased mu-opioid but unaltered dopamine D2 receptor availability in the brain. *J Neurosci* 2015; **35**(9): 3959-3965.
  - 13 female subjects scanned with Discovery 690 PET/CT (GE Healthcare).

- Nummenmaa L *et al.* Brain Basis of Psychopathy in Criminal Offenders and General Population. *Cerebral Cortex* (in press), https://emotion.utu.fi/wp-content/uploads/2021/03/Nummenmaa_et_al_CC_21.pdf
  - 13 male subjects scanned with GE Discovery VCT PET/CT (GE Healthcare).

- Neuromolecular Risk Factors for Obesity (PROSPECT), ClinicalTrials.gov Identifier: NCT03106688.
  https://www.clinicaltrials.gov/ct2/show/NCT03106688?term=neuromolecular+risk+factors+for+obesity&draw=2&rank=1
  - 39 male subjects scanned with GE Discovery VCT PET/CT (GE Healthcare). All 35 [18F]FMPEP-$d_2$ scans were from this subsample and also scanned with GE Discovery VCT PET/CT.
Table of the $p$-values for descriptive correlations

**Supplementary Table 3.** The $p$-values for corresponding Pearson correlation coefficients in the sample of 92 subjects (70 males and 22 females) scanned with $[^{11}\text{C}]$carfentanil.

|              | DEBQ Total | DEBQ Emotional | DEBQ External | DEBQ Restrained | BMI    | Age    |
|--------------|------------|----------------|---------------|-----------------|--------|--------|
| DEBQ Total   | 1.000      | $<$0.001       | $<$0.001      | $<$0.001        | 0.137  | 0.119  |
| DEBQ Emotional | $<$0.001  | 1.000          | 0.001         | 0.028           | 0.753  | 0.822  |
| DEBQ External | $<$0.001  | 0.001          | 1.000         | 0.267           | 0.728  | 0.676  |
| DEBQ Restrained | $<$0.001 | 0.028          | 0.267         | 1.000           | 0.009  | $<$0.001 |
| BMI          | 0.137      | 0.753          | 0.728         | 0.009           | 1.000  | 0.352  |
| Age          | 0.119      | 0.822          | 0.676         | $<$0.001        | 0.352  | 1.000  |
Peak voxel coordinates for the full volume associations

**Supplementary Table 4.** Peak voxel coordinates for the full volume associations.

Negative association between $[^{11}\text{C}]$carfentanil $BP_{ND}$ and External eating score ($n = 92$)

| Brain region                  | MNI coordinates | T-score |
|-------------------------------|-----------------|---------|
| Right middle temporal gyrus   | x: 66, y: -48, z: 6 | 4.32    |
| Right postcentral gyrus       | x: 54, y: -10, z: 18 | 3.85    |
| Right anterior insula         | x: 34, y: 20, z: 12 | 3.85    |
| Cerebellum                    | x: 26, y: -66, z: -18 | 3.87    |
|                               | x: -16, y: -60, z: -22 | 3.48    |
|                               | x: 26, y: -52, z: -18 | 3.39    |

Negative association between $[^{18}\text{F}]$FMPEP-$d_2$ $V_T$ and Total DEBQ score ($n = 35$)

| Brain region                  | MNI coordinates | T-score |
|-------------------------------|-----------------|---------|
| Left superior temporal gyrus  | x: -33, y: 8, z: -33 | 4.00    |
|                               | x: -48, y: 7, z: -19 | 3.70    |
| Left parahippocampus          | x: -21, y: 1, z: -23 | 3.67    |
| Right parahippocampus         | x: 30, y: -35, z: -17 | 3.63    |
| Right caudate                 | x: 20, y: -21, z: 23 | 3.08    |
| Right cerebellum              | x: 30, y: -32, z: -30 | 2.96    |
| Left middle frontal gyrus     | x: -23, y: 57, z: -16 | 3.42    |
| Anterior cingulate cortex     | x: 2, y: 2, z: -7  | 3.21    |
| Anterior caudate              | x: -1, y: 14, z: -3 | 3.18    |
| Right insula                  | x: 42, y: -33, z: 20 | 3.42    |
| Right precentral gyrus        | x: 56, y: 0, z: 13 | 3.39    |
| Right insula                  | x: 37, y: -12, z: 16 | 3.24    |

Cluster forming threshold $p < 0.01$, FWE corrected at cluster level. Age and PET scanner as covariates in the $[^{11}\text{C}]$carfentanil model, age as a covariate in the $[^{18}\text{F}]$FMPEP-$d_2$ model.
Scan acquisition and modeling in the PROSPECT

Supplementary Text 1. The acquisition and modeling of the 35 $[^{18}\text{F}]\text{FMPEP-}d_2$ scans and 39 $[^{11}\text{C}]\text{carfentanil}$ scans from the PROSPECT project.

The 35 $[^{18}\text{F}]\text{FMPEP-}d_2$ scans and 39 $[^{11}\text{C}]\text{carfentanil}$ scans are derived from the project “Neuromolecular Risk Factors for Obesity” (PROSPECT), which is preregistered to ClinicalTrials.gov (Identifier: NCT03106688). Subjects fasted at least 6 hours before the scans. The PET scans were done on separate days.

$[^{18}\text{F}]\text{FMPEP-}d_2$ scans

Two cannulas were inserted before the scan, one in an antecubital vein for $[^{18}\text{F}]\text{FMPEP-}d_2$ injection and one in the contralateral antecubital vein for blood sampling. Before the scan, venous blood samples were drawn to measure hematocrit. 147–215 MBq of $[^{18}\text{F}]\text{FMPEP-}d_2$ was administered intravenously and brain’s radioactivity was followed 60 minutes (15 frames). A peripheral PET scan was conducted on neck (12 min) and abdominal (9 min) regions. Brain’s radioactivity was then followed 9 minutes (3 x 180-second frames) starting at a time point 94 ± 2 min. Arterialized venous blood samples to measure plasma activity were drawn contralaterally to injection site at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4.5, 7.5, 11, 15, 20, 25, 30, 35, 40, 45, 50 and 60 min from the injection, and at subsequent time points (min from the regional scan start): neck (2 and 6 min), abdomen (4.5 min) and late brain scan (4.5 min). Additional blood samples for $[^{18}\text{F}]\text{FMPEP-}d_2$ metabolite analysis were drawn before the scan and at 4.5, 11, 15, 20, 30, 45 and 60 min from the injection, and at subsequent time points (min from the regional scan start): neck (2 and 6 min), abdomen (4.5 min).

$CB_1 R$ availability was quantified as $[^{18}\text{F}]\text{FMPEP-}d_2$ volume of distribution ($V_t$) using graphical analysis (Logan). The frames starting at 36 minutes and later since injection were used in the model fitting, since Logan plots became linear after 36 minutes. Plasma activities were
corrected for plasma metabolites as described previously\(^2\). We were unable to obtain metabolite data from two subjects due to laboratory measurement issues, so we used the mean metabolite fraction of the group for these two subjects.

\[^{11}C\]carfentanil scans

A cannula was inserted before the scan in an antecubital vein for \[^{11}C\]carfentanil injection. 223–279 MBq of \[^{11}C\]carfentanil was administered intravenously and the brain’s radioactivity was followed 51 minutes (13 frames). The modeling of the \[^{11}C\]carfentanil data and the acquisition of binding potentials (\(BP_{ND}\)) has been previously described\(^3\).
Complementary $[^{11}\text{C}]$carfentanil analyses

Supplementary Text 2. Summary of the complementary $[^{11}\text{C}]$carfentanil analyses.

Smoking status did not influence $[^{11}\text{C}]$carfentanil results. When adjusting simultaneously for smoking, sex and BMI (in addition to age and scanner), the association with $[^{11}\text{C}]$carfentanil binding potential ($BP_{\text{ND}}$) and External eating score remained essentially the same (significant at cluster forming threshold $p < 0.02$, FWE corrected).

The male subsample

In the subsample of 70 males, the associations between External eating score and $\mu$-opioid receptor availability were mostly similar than with the full sample, associations in caudatus being slightly less prominent (significant at cluster forming threshold $p < 0.05$, FWE corrected).

The female subsample

In the subsample of 22 females, there were no statistically significant associations between External eating score and central $\mu$-opioid receptor availability. This is potentially due to the relatively low number of female subjects.
Supplementary Figure 1. Descriptive correlations between the Dutch Eating Behaviour Questionnaire (DEBQ) total and subscale scores, age and body mass index (BMI) in the sample of 92 subjects (70 males and 22 females) scanned with \(^{11}\text{C}\)carfentanil. The numbers indicate Pearson correlation coefficients. \(p < 0.05\) correlations are marked with boldface.

Since Restrained eating score was higher in females than in males and females were also older than males (Table 1), we examined the correlations of age and restrained eating also in both female and male subgroups. Restrained eating correlated positively with age in both groups, but more strongly in the female sample (females \(r = 0.33, p = 0.01\); males \(r = 0.25, p = 0.03\)).
Visualization of regional associations in three representative regions of interest

**Supplementary Figure 2.** Visualization of regional associations in three representative regions of interest. Upper row: Scatterplots show the associations of External eating score and \([^{11}\text{C}]\text{carfentanil binding potential (}\text{BP}_{\text{ND}}\text{) in putamen, nucleus accumbens (nAcc) and caudate (92 subjects, LS-regression line with 95% CI)}.\) Lower row: Scatterplots show the associations of Total DEBQ score and \([^{18}\text{F}]\text{FMPEP-d2 volume of distribution (}\text{VT}\text{) in putamen, nucleus accumbens (nAcc) and caudate (35 subjects, LS-regression line with 95% CI)}.\)
Regional correlations between MOR and CB$_1$R availabilities

**Supplementary Figure 3.** Descriptive correlations between [$^{11}$C]carfentanil binding potential $BP_{ND}$ (bpnd) and [$^{18}$F]FMPEP-$d_2$ volume of distribution $V_T$ (vt) in 10 regions of interest in the subsample of 35 subjects scanned with both tracers. The numbers indicate Pearson correlation coefficients (for all, $p > 0.05$). The abbreviations stand for amy = amygdala, cau = caudatus, cer = cerebellum, dacc = dorsal anterior cingulate cortex, ins = insula, midtemp = middle temporal cortex, nacc = nucleus accumbens, ofc = orbitofrontal cortex, put = putamen, tha = thalamus.
External eating and µ-opioid receptor availability in males

Supplementary Figure 4. Brain regions where higher External eating score associated with lower \[^{11}\text{C}]\text{carfentanil}\) binding potential (\(BP_{\text{ND}}\)) in 70 males, age and PET scanner as nuisance covariates. Shown are clusters where \(p < 0.05\), FWE corrected at cluster level.
References

1. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. *Nuclear Medicine and Biology* 2000; **27**(7): 661-670.

2. Lahesmaa M et al. Cannabinoid type 1 receptors are upregulated during acute activation of brown adipose tissue. *Diabetes* 2018; **67**(7): 1226-1236.

3. Kantonen T et al. Interindividual variability and lateralization of µ-opioid receptors in the human brain. *NeuroImage* 2020; **217**: 116922.